Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months

Noor, Ramadhani A.; Thiesen, M.; Mordmüller, Benjamin; Milligan, Paul; Atuguba, Frank; Sirima, Sodiomon B.; Issifou, Saadou; Bojang, Kalifa; Kironde, Fred; Tiono, Alfred B.; Okech, Brenda; Chilengi, Roma; Ngoa, Ateba; Mukasa, Kaddu; Jepsen, Søren

doi:10.1186/1475-2875-9-s2-p26

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[68][69][70][71][72] The latter combination vaccine, GMZ2, has progressed to a multicenter Phase IIB trial in Africa. 73 To our knowledge, GLURP-R2 has not yet been tested in any human vaccine. The present study's results support the further and continued use of CSP, LSA-1, GLURP-R2, and GLURP-R0 as vaccine candidate antigens, including vaccines for use in areas of low transmission.…”

Section: Discussionmentioning

confidence: 99%

Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission

Hamre

Ondigo

Hodges

et al. 2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Immune correlates of protection against clinical malaria are difficult to ascertain in low-transmission areas because of the limited number of malaria cases. We collected blood samples from 5,753 individuals in a Kenyan highland area, ascertained malaria incidence in this population over the next 6 years, and then compared antibody responses to 11 Plasmodium falciparum vaccine candidate antigens in individuals who did versus did not develop clinical malaria in a nested case-control study (154 cases and 462 controls). Individuals were matched by age and village. Antigens tested included circumsporozoite protein (CSP), liver-stage antigen (LSA)-1, apical membrane antigen-1 FVO and 3D7 strains, erythrocyte-binding antigen-175, erythrocyte-binding protein-2, merozoite surface protein (MSP)-1 FVO and 3D7 strains, MSP-3, and glutamate-rich protein (GLURP) N-terminal non-repetitive (R0) and C-terminal repetitive (R2) regions. After adjustment for potential confounding factors, the presence of antibodies to LSA-1, GLURP-R2, or GLURP-R0 was associated with decreased odds of developing clinical malaria (odds ratio [OR], [95%

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission

Hamre

Ondigo

Hodges

et al. 2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months

Abstract: Noor et al.: Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months.

Cited by 1 publication

References 0 publications

Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission

Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission

Contact Info

Product

Resources

About